Abstract 20081: Predicting Risk of Endovascular Device Infection in Patients with Staphylococcus aureus Bacteremia
Objectives: Clinicians need to identify which patients presenting with S. aureus bacteremia (SAB) have underlying cardiovascular implantable electronic device (CIED) infection and therefore need device extraction. The goal of this study was to identify clinical predictors of CIED infection in patients presenting with SAB.
Methods: We retrospectively reviewed all cases of SAB in CIED recipients at Mayo Clinic from Jan 2001 to Dec 2011. CIED infection was defined using clinical, microbiologic and echocardiographic criteria. Patients who presented with clinical signs of CIED pocket infection were excluded. A multivariable model was developed to identify independent predictors of CIED infection. Model discrimination was summarized using the area under a receiver operating characteristics curve (AUC).
Results: Among the 131 patients with SAB and CIED, 45 (34%) had underlying CIED infection. Permanent pacemaker (PPM) devices (OR 3.90, 95% CI 1.65-9.23, p=0.002), >1 device-related procedure (OR 3.30, 95% CI 1.23-8.86, p=0.018), and duration of SAB ≥4 days (OR 5.54, 95% CI 3.32-13.23, p <0.001) were independently associated with an increased risk of CIED infection. The AUC for this multivariable model was 0.79 indicating good discriminatory capacity to separate SAB patients with and without CIED infection. Various combinations of these three features and the corresponding predicted probabilities of CIED infection are summarized in Table.
Conclusions: An individual patient’s risk of underlying CIED infection can be calculated based on the type of device, number of device-related procedures, and duration of SAB. Patients without any of these high-risk features have very low risk of underlying CIED infection and may be monitored closely without immediate device extraction.
Author Disclosures: M. Sohail: Research Grant; Modest; TYRX Inc., Medtronic. Consultant/Advisory Board; Modest; Spectranetics. B. Palraj: None. S. Khalid: None. D. Uslan: Honoraria; Modest; BIOTRONIK, Medtronic. Consultant/Advisory Board; Modest; Medtronic/TYRX Inc.. F. Al-Saffar: None. P. Friedman: Research Grant; Modest; Medtronic, Guidant, Astra Zeneca, St. Jude, Bard. Consultant/Advisory Board; Modest; Medtronic, Guidant, Astra Zeneca. C. Lohse: None. W. Wilson: None. J. Steckelberg: None. L. Baddour: Other; Modest; Royalty: UpToDate Inc..
This research has received full or partial funding support from the American Heart Association.
- © 2014 by American Heart Association, Inc.